NYSEHealth CareHealth Care EquipmentS&P MidCap 400
$71.05
-10.39 (-12.76%)
Close of Nov 06, 2026 · end-of-day data
GMED 8-K filings in 2026
Every material Form 8-K Globus Medical filed with the SEC in 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Globus Medical reported third quarter 2026 worldwide net sales of $763.7 million, representing a 0.7% decrease compared to the same period in 2025, alongside GAAP net income of $141.2 million. The company updated its full-year 2026 revenue guidance to $3.09 billion and announced a $500 million increase to its share repurchase program.
Worldwide net sales were $763.7 million for the third quarter ended September 30, 2026, down 0.7% year-over-year.
GAAP diluted earnings per share increased 18.2% to $1.04 for the quarter.
The Board authorized an additional $500.0 million share repurchase program increase on November 2, 2026.
Full-year 2026 revenue guidance was updated to $3.09 billion.
Globus Medical reported second-quarter 2026 worldwide net sales of $789.6 million, up 5.9%, and raised its full-year 2026 non-GAAP diluted EPS guidance to $4.95 to $5.05 from $4.70 to $4.80. GAAP diluted EPS fell 26.2% to $1.10, mainly because of a $110.5 million bargain purchase gain recorded in the prior-year quarter related to the Nevro acquisition. Full-year 2026 revenue guidance of $3.18 billion to $3.22 billion was reaffirmed.
Q2 2026 worldwide net sales were $789.6 million, up 5.9% as reported and 5.6% on a constant currency basis.
Non-GAAP diluted EPS was $1.34, up 55.8% from $0.86; GAAP diluted EPS was $1.10, down 26.2% from $1.49.
Full-year 2026 non-GAAP diluted EPS guidance raised to $4.95 to $5.05 from $4.70 to $4.80.
Full-year 2026 revenue guidance reaffirmed at $3.18 billion to $3.22 billion.
At its June 3, 2026 annual meeting, Globus Medical stockholders approved an amendment raising the shares authorized under its 2021 Equity Incentive Plan by 1,000,000, to 12,000,000 Class A shares. Stockholders also re-elected director Keith W. Pfeil and elected Robert A. Douglas to Class II terms, ratified Deloitte & Touche LLP as auditor for 2026, and approved executive compensation on an advisory basis.
Equity plan amendment: 246,228,534 for, 75,266,538 against, 79,135 abstain, 6,902,949 broker non-votes
Total shares authorized under the plan rise to 12,000,000 from 11,000,000 for incentive stock options, which are now 12,000,000
Director votes: Keith W. Pfeil 293,453,432 for and 28,120,775 withheld; Robert A. Douglas 311,683,904 for and 9,890,303 withheld
Deloitte & Touche LLP ratified for fiscal year ending December 31, 2026, with 327,965,803 for and 467,955 against
Globus Medical reported first-quarter 2026 net sales of $759.9 million, up 27.0% from a year earlier, and GAAP net income of $124.3 million, up 64.7%. The company reaffirmed its full-year 2026 revenue guidance of $3.18 billion to $3.22 billion and raised its non-GAAP diluted EPS guidance to $4.70 to $4.80 from $4.40 to $4.50.
Q1 2026 net sales were $759.9 million, up 27.0%; base business excluding Nevro rose 13.2% to $677.2 million
GAAP diluted EPS was $0.90 versus $0.54 a year earlier; non-GAAP diluted EPS was $1.12 versus $0.68
Full-year 2026 revenue guidance reaffirmed at $3.18 billion to $3.22 billion
Non-GAAP diluted EPS guidance raised to $4.70 to $4.80 from $4.40 to $4.50
Globus Medical director John A. DeFord, Ph.D., resigned from the Board of Directors effective immediately on March 23, 2026, and said the decision was not a result of any disagreement with the company. He will not seek re-election at the Annual Meeting of Stockholders on June 3, 2026. The filing describes a board departure with no change to financial results or guidance.
Resignation effective immediately, announced March 23, 2026
Company states the decision was not due to any disagreement with the company
Dr. DeFord would not have stood for re-election at the June 3, 2026 annual meeting
Chairman David C. Paul thanked him for his work on the NuVasive merger and the Nominating and Governance Committee
Globus Medical reported fourth-quarter 2025 worldwide net sales of $826.4 million, up 25.7%, and GAAP diluted EPS of $1.03 versus $0.19 a year earlier. The company reaffirmed 2026 revenue guidance of $3.18 to $3.22 billion and raised its non-GAAP diluted EPS guidance to $4.40 to $4.50 from $4.30 to $4.40. The sales growth includes the Nevro acquisition; the base business excluding Nevro grew 10.6% in the quarter.
Q4 2025 worldwide net sales were $826.4 million, up 25.7%; base business excluding Nevro rose 10.6%.
Q4 2025 GAAP net income was $140.6 million; GAAP diluted EPS was $1.03 versus $0.19 in Q4 2024.
2026 revenue guidance reaffirmed at $3.18 to $3.22 billion; non-GAAP diluted EPS guidance raised to $4.40 to $4.50 from $4.30 to $4.40.
Globus Medical said preliminary unaudited sales were about $823.2 million for the fourth quarter of 2025 and about $2.936 billion for full year 2025, up 25.2% and 16.5% on an as-reported basis. The company also set 2026 revenue guidance of $3.18 billion to $3.22 billion and non-GAAP diluted EPS of $4.30 to $4.40, though the figures remain subject to change until final results are released on February 24, 2026.
Q4 2025 sales of approximately $823.2 million, up 25.2% from Q4 2024 on an as-reported basis
Q4 2025 base business revenue, excluding Nevro, was $723.3 million, up 10.0%, led by US Spine
FY2025 sales of approximately $2.936 billion, up 16.5%; 2026 revenue guidance $3.18 billion to $3.22 billion
2026 non-GAAP diluted EPS guidance of $4.30 to $4.40; final results due February 24, 2026
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Globus Medical filing is on SEC EDGAR ↗. 8-K briefs of other companies →